Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sildenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 19/20 | 0.98 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.98 |
| ▸ | PDE2A | O00408 | 1/20 | 0.98 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.98 |
| ▸ | PDE6D | O43924 | 1/20 | 0.98 |
| ▸ | PDE8A | O60658 | 1/20 | 0.98 |
| ▸ | PDE9A | O76083 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | PDE6A | P16499 | 1/20 | 0.98 |
| ▸ | PDE6G | P18545 | 1/20 | 0.98 |
| ▸ | PDE4A | P27815 | 1/20 | 0.98 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.98 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | PDE6B | P35913 | 1/20 | 0.98 |
| ▸ | PDE6C | P51160 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sildenafil SCHEMBL20544481 | 0.99 | PDE5A (0.97) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL5683880 | 0.99 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL29361663 | 0.99 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL1895 | 0.99 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL5691322 | 0.98 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL6689399 | 0.98 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL1801562 | 0.98 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL19410952 | 0.98 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL7915871 | 0.98 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL3399278 | 0.97 | PDE5A (0.95) | PDE5APDE3BPDE3AABCC4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119970684-A | Sildenafil oral solution film and preparation method thereof | 四川科伦药物研究院有限公司 | 2025-05-13 | — | — | CN | claimed |
| US-20200338080-A1 | TOPICAL FORMULATION CONTAINING PAPAVERINE AND SILDENAFIL AND USES THEREOF | TAWAR VINOD (CA) | 2020-10-29 | — | — | US | claimed |
| US-20130274235-A1 | TREATMENT OF MOTOR NEURON DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-10-17 | — | — | US | claimed |
| WO-2012048330-A2 | TREATMENT OF MOTOR NEURON DISEASE | THE MCLEAN HOSPITAL CORPORATION (US) | 2012-04-12 | — | — | WO | claimed |
| WO-2007110559-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHIC FORMS OF SILDENAFIL | PLIVA HRVATSKA D.O.O. (HR) | 2007-10-04 | — | — | WO | claimed |
| WO-2006069806-A1 | PHARMACEUTICAL COMPOSITION COMPRINSING A 2,5-DIHYDROXYBENZENESULFONIC COMPOUNDS, A POTASSIUM ION CHANNEL MODULATOR AND A PHOSPHODIESTERASE TYPE 5 INHIBITOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | claimed |
| EP-1676573-A1 | Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-05 | — | — | EP | claimed |
| EP-1652521-A1 | Pharmaceutical composition of sildenafil and a large conductance Ca(2+) activated K+ channels activator | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-05-03 | — | — | EP | claimed |
| US-6200591-B1 | HIGH SPEED, ACCUARCY SUPPLYING THROUGH NOSE | NEW MILLENNIUM PHARMACEUTICAL RESEARCH, INC. | 2001-03-13 | — | — | US | claimed |
| US-12622971-B2 | Linear polysaccharide based film products | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| CN-119970684-A | Sildenafil oral solution film and preparation method thereof | 四川科伦药物研究院有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250134804-A1 | Solid Dosage Form | IX BIOPHARMA LTD (SG) | 2025-05-01 | — | — | US | disclosed |
| US-20250041309-A1 | USE OF AILDENAFIL OR SALT THEREOF IN PREPARATION OF MEDICINE FOR PREVENTING OR TREATING ISCHEMIC BRAIN DAMAGE | ZHENAO JINYINHUA PHARMACEUTICAL (CN) | 2025-02-06 | — | — | US | disclosed |
| US-12186426-B2 | Solid dosage form | IX BIOPHARMA LTD. (SG) | 2025-01-07 | — | — | US | disclosed |
| WO-2001035926-A2 | AN IMPROVED PHARMACEUTICAL COMPOSITION FOR TREATING MALE ERECTILE DYSFUNCTION | NATCO PHARMA LIMITED (IN) | 2001-05-25 | — | — | WO | disclosed |
| US-6200591-B1 | HIGH SPEED, ACCUARCY SUPPLYING THROUGH NOSE | NEW MILLENNIUM PHARMACEUTICAL RESEARCH, INC. | 2001-03-13 | — | — | US | disclosed |
| WO-2000012076-A9 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000023056-A2 | THE USE OF DOPAMINERGIC AGENTS IN THE MANAGEMENT OF SEXUAL DYSFUNCTION | MCGILL UNIVERSITY (CA) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000012076-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999066933-A1 | NASAL ADMINISTRATION OF SILDENAFIL FOR THE TREATMENT OF ERECTILE DYSFUNCTION | NEW MILLENNIUM PHARMACEUTICAL RESEARCH, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041309-A1 | USE OF AILDENAFIL OR SALT THEREOF IN PREPARATION OF MEDICINE FOR PREVENTING OR TREATING ISCHEMIC BRAIN DAMAGE | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE3B 4/4885PDE3A 2/4885 |
| US-12622971-B2 | Linear polysaccharide based film products | SORD, SMCHD1, PLEC | PDE5A 448/4885PDE3B 758/4885PDE3A 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.